Joel R. Hecht, Elena Elez, Cathy Eng, Peter Gibbs, Jenny F. Seligmann, Rui-Hua Xu, Kensei Yamaguchi, Chao-Yuan Wang, Hao Wei Teng, Leonardo Trani, Honeylet Wortman-Vayn, Zhengyu Jiang, Brooke Diorio, Patricia A. Lorenzini, Christine Baudelet, Seema Niphadkar Sethi, Mahadi Baig, Chiara Cremolini. "OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic
            <i>RAS/BRAF</i>
            wild-type colorectal cancer.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.tps3638